Background illustration for clinical trials search

Paid Clinical Trials Montreal

Discover 1,169 paid clinical trials in Montreal, Quebec. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

for
Oligometastatic Prostate Cancer (OMPC)
Location: Montreal, Ottawa, Quebec, Syracuse NY, Boston MA,
Sponsor: Novartis Pharmaceuticals

Sex: Male

Age: 18 - 70+

Code: NCT05939414

Phase 3, Recruiting

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

for
Aortic Stenosis
Location: Montreal, Quebec, Ottawa, Albany NY, Boston MA,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 50 - 70+

Code: NCT05646381

Phase 2, Recruiting

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

for
Solid Tumor
Location: Montreal, New York NY, Toronto, London, Pittsburgh PA,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18+

Code: NCT04939610

Phase 1, Phase 2, Recruiting

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

for
IC-MPGN
Location: Montreal, Boston MA, Toronto, Etobicoke, New York NY,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 12 - 60

Code: NCT05755386

Phase 3, Recruiting

CAR-T Long Term Follow Up (LTFU) Study

for
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program,
Location: Montreal, Boston MA, Toronto, Hamilton, Philadelphia PA,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 0 - 70+

Code: NCT02445222

Phase 3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

for
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer,
Location: Montreal, Boston MA, Toronto, Grand Rapids MI,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18 - 70+

Code: NCT06562192

Phase 1, Recruiting

Asciminib Roll-over Study

for
Chronic Myelogenous Leukemia,
Location: Montreal, New York NY, Ann Arbor MI, Cincinnati OH,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 7 - 70+

Code: NCT04877522

Phase 4, Recruiting

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

for
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer,
Location: Montreal, Princeton NJ
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07261631

Phase 1, Recruiting

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

for
Secondary Progressive Multiple Sclerosis (SPMS)
Location: Montreal, Sherbrooke, Ottawa, Levis, Quebec,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18 - 65

Code: NCT07225504

Phase 3, Recruiting

A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

for
Atrial Fibrillation
Location: Montreal, Quebec, Sherbrooke, Newmarket, Toronto,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07217067

Phase 2, Recruiting

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Location: Montreal, Durham NC, Myrtle Beach SC, Iowa City IA,
Sponsor: Novartis Pharmaceuticals

Sex: Male

Age: 18+

Code: NCT07190300

Phase 1, Phase 2, Recruiting

A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

for
Sjögren's Disease
Location: Sherbrooke, Trois-Rivieres, Rimouski, Willow Grove PA,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18 - 70+

Code: NCT07737743

Phase 2, Recruiting

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

for
Hidradenitis Suppurativa
Location: Montreal, Quebec, Rochester NY, New York NY, London,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18 - 70+

Code: NCT07665437

Phase 3, Recruiting

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

for
Small Cell Lung Carcinoma,
Location: Montreal, Boston MA, Royal Oak MI, Iowa City IA,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18 - 70+

Code: NCT07006727

Phase 1, Recruiting

Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors

for
Breast Cancer, Non-small Cell Lung Cancer (NSCLC),
Location: Montreal, New York NY, Omaha NE
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07660055

Phase 1, Recruiting

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

for
Chronic Myelogenous Leukemia,
Location: Montreal, New York NY, New Brunswick NJ, Cincinnati OH,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 1 - 18

Code: NCT07354074

Phase 2, Recruiting

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Location: Montreal, Boston MA, Toronto, Dallas TX
Sponsor: Novartis Pharmaceuticals

Sex: Male

Age: 18+

Code: NCT07570979

Phase 1, Recruiting

A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

for
Heart Failure With Reduced Ejection Fraction
Location: Montreal, Jacksonville FL, Winter Park FL, Inverness FL,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18 - 70+

Code: NCT07465653

Phase 1, Recruiting

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

for
Somatostatin Receptor Positive (SSTR+),
Location: Montreal, Hartford CT, New Haven CT, New York NY,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 12 - 70+

Code: NCT06784752

Phase 3, Recruiting

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

for
Relapsing Multiple Sclerosis
Location: Montreal, Levis, Burlington MA, Foxborough MA,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 40 - 70

Code: NCT06846281

Phase 3, Recruiting